Q-omics provides the consensus-scored FBXL14 profile across patient tissues and cancer cell-line models. FBXL14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, FBXL14 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, FBXL14 RNA expression shows 20,300 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, BLCA, and ACC as cancer lineages where FBXL14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL14 survival associations across molecular data types. FBXL14 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL14 RNA expression–survival associations across cancer types. High FBXL14 expression shows unfavorable associations in CESC, but favorable associations in SCLC, KIRC, STAD, READ and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for FBXL14 RNA expression.
This table summarizes FBXL14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXL14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL14 shows lower tumor expression in THCA and higher tumor expression in BLCA, CHOL, STAD, BRCA and ESCA. The BLCA box plot shows higher FBXL14 RNA expression in tumor versus normal tissue (log2 FC = +0.557, t-test p = .004).
This table shows molecular features associated with FBXL14 in patient tissues and cancer cell lines. In patient samples, FBXL14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
